Month: October 2018

Andarix Pharmaceuticals to Present Lung Cancer Clinical Trial Results at the Society of Nuclear Medicine Meeting

Oct 31, 2018

—

by

cadams

in Article

clinical study, conference, lung cancer, oncology, radiotherapy, targeted therapy

ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present the results of its latest clinical trial in lung cancer patients. The trial focused on the administration of Tozaride, the company’s lead candidate in neuroendocrine lung cancer patients. The abstract is entitled “Targeted Clinical Study…
Andarix Pharmaceuticals to present at the CBI Basket and Umbrella Trials for Oncology Conference

Oct 25, 2018

—

by

cadams

in Article

conference, oncology, targeted therapy

ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present strategies for broad-based or basket clinical trials in lung cancer. The presentation will take place at the CBI Basket and Umbrella Trials for Oncology Conference in Philadelphia, Pennsylvania on Oct 17-18, 2018.